Opdivo Qvantig represents the first and only subcutaneously administered PD-1 inhibitor Opdivo Qvantig demonstrated consistent efficacy and showed a comparable safety profile to IV Opdivo in the Phase 3 CheckMate-67T trial SAN DIEGO, Dec. 30, 2024 /PRNewswire/ — Halozyme Therapeutics,…

SAN DIEGO, Dec. 30, 2024 /PRNewswire/ — Robbins Geller Rudman & Dowd LLP announces that purchasers of Celsius Holdings, Inc. (NASDAQ: CELH) common stock between February 29, 2024 and September 4, 2024, both dates inclusive (the “Class Period”), have until Tuesday, January 21, 2025 to…

NEW YORK and DUBAI, Dec. 30, 2024 /PRNewswire/ — Stagwell (NASDAQ: STGW), the challenger network built to transform marketing, today announced it has entered into an agreement to acquire Create. Group, the Middle East’s leading strategic digital communications group. The company will…

CALGARY, AB, Dec. 30, 2024 /PRNewswire/ – High Tide Inc. (“High Tide” or the “Company”) (Nasdaq: HITI) (TSXV: HITI) (FSE: 2LYA), the high-impact, retail-forward enterprise built to deliver real-world value across every component of cannabis, is pleased to reflect on its key milestones for…

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.